Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor Enasidenib

Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of mutant IDH2, produces a clinical r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Nat Med
Hlavní autoři: Quek, Lynn, David, Muriel D., Kennedy, Alison, Metzner, Marlen, Amatangelo, Michael, Shih, Alan, Stoilova, Bilyana, Quivoron, Cyril, Heiblig, Maël, Willekens, Christophe, Saada, Véronique, Alsafadi, Samar, Vijayabaskar, MS, Peniket, Andy, Bernard, Oliver A, Agresta, Sam, Yen, Katharine, MacBeth, Kyle, Stein, Eytan, Vassiliou, George S., Levine, Ross, De Botton, Stephane, Thakurta, Anjan, Penard-Lacronique, Virginie, Vyas, Paresh
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6925974/
https://ncbi.nlm.nih.gov/pubmed/30013198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0115-6
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky